The FDA approved the ATTUNE TKA system in December 2010 under their 510(k) clearance program. DePuy, a subsidiary of Johnson & Johnson, has sold approximately 400,000 ATTUNE knee implants since it was first released to the public in March 2013. Orthopedic surgeons and patients alike have complained of the unusually high premature failure rate of the implant. As of June 2017, there have been 1,400 reports of device failure in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. Six hundred thirty-three of these reports cited revision surgery. Artificial knees last 15 to 20 years for most patients, but the ATTUNE knee replacement has failed in as little as one to two years. The glue that holds the Attune knee replacement in place may not adequately stick to the tibial component. This loosens the tibial component at the implant-cement interface, causing the entire knee replacement to destabilize.